Evinacumab vs SHR-1918

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Homozygous Familial Hypercholesterolemia

Shared mechanism: ANGPTL3 · full Homozygous Familial Hypercholesterolemia pipeline

Evinacumab · Evkeeza

Marketed by Regeneron Pharmaceuticals and partners

Approved in Homozygous Familial Hypercholesterolemiamonoclonal antibody
Partial signal

NCT03399786 · Phase 3 · completed

The trial randomized 65 participants to evinacumab or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary LDL-C endpoint was statistically significantly improved with evinacumab, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure.

Reported efficacy

Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand): Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5) (met)

Result source: NCT03399786

SHR-1918

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Homozygous Familial Hypercholesterolemiamonoclonal antibody
Partial signal

NCT06723652 · Phase 3 · completed

This is a randomized, quadruple-blinded, placebo-controlled trial with a disease-defining efficacy endpoint (percent change in LDL cholesterol), but results have not been posted, so whether SHR-1918 lowered LDL cholesterol significantly versus placebo cannot yet be confirmed from this record.

Reported efficacy

Percent change in calculated LDL-C from baseline to week 12: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 (met)

Result source: NCT06723652

Results for Homozygous Familial Hypercholesterolemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

SHR-1918
LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 NCT06723652 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Evinacumab

Apo B -41.4% (n=43) vs -4.5% (n=22) placebo @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Non-HDL-C -49.7% (n=43) vs 2% (n=22) placebo @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Total Cholesterol -47.4% (n=43) vs 1% (n=22) placebo @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Triglycerides -55% (n=43) vs -4.6% (n=22) placebo @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Lp(a -5.5% (n=43) vs -3.6% (n=22) placebo @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Apo B -41.3% (n=14) @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
No placebo or comparator arm
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 6 more results
-39.74% (n=116) @ 8wk
NCT03409744 · Phase 3 · monotherapy
-36.98% (n=116) @ 24wk
NCT03409744 · Phase 3 · monotherapy
-35.85% (n=116) @ 48wk
NCT03409744 · Phase 3 · monotherapy
-37.6% (n=116) @ 72wk
NCT03409744 · Phase 3 · monotherapy
-32.54% (n=116) @ 96wk
NCT03409744 · Phase 3 · monotherapy
-27.73% (n=116) @ 120wk
NCT03409744 · Phase 3 · monotherapy
Non-HDL-C -48.9% (n=14) @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
No placebo or comparator arm
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 6 more results
-48.47% (n=116) @ 8wk
NCT03409744 · Phase 3 · monotherapy
-46.14% (n=116) @ 24wk
NCT03409744 · Phase 3 · monotherapy
-45.15% (n=116) @ 48wk
NCT03409744 · Phase 3 · monotherapy
-46.69% (n=116) @ 72wk
NCT03409744 · Phase 3 · monotherapy
-40.88% (n=116) @ 96wk
NCT03409744 · Phase 3 · monotherapy
-35.85% (n=116) @ 120wk
NCT03409744 · Phase 3 · monotherapy
Total Cholesterol -49.1% (n=14) @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
No placebo or comparator arm
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 6 more results
-47.04% (n=116) @ 8wk
NCT03409744 · Phase 3 · monotherapy
-44.17% (n=116) @ 24wk
NCT03409744 · Phase 3 · monotherapy
-43.78% (n=116) @ 48wk
NCT03409744 · Phase 3 · monotherapy
-44.58% (n=116) @ 72wk
NCT03409744 · Phase 3 · monotherapy
-40.33% (n=116) @ 96wk
NCT03409744 · Phase 3 · monotherapy
-36.92% (n=116) @ 120wk
NCT03409744 · Phase 3 · monotherapy
Lp(a -37.3% (n=14) @ 24wk15 mg/kg IV Q4W
percent change · % of baseline
No placebo or comparator arm
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
TG -45.97% (n=116) @ 8wk
percent change · % of baseline
No placebo or comparator arm
NCT03409744 · Phase 3 · monotherapy
show 5 more results
-46.93% (n=116) @ 24wk
NCT03409744 · Phase 3 · monotherapy
-43.25% (n=116) @ 48wk
NCT03409744 · Phase 3 · monotherapy
-46.5% (n=116) @ 72wk
NCT03409744 · Phase 3 · monotherapy
-48.28% (n=116) @ 96wk
NCT03409744 · Phase 3 · monotherapy
-42.06% (n=116) @ 120wk
NCT03409744 · Phase 3 · monotherapy
Available safety results

Evinacumab

Dropout rate
0%15 mg/kg
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 8 more results
—15 mg/kg
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%15 mg/kg IV
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%15 mg/kg IV Q4W
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—
NCT03409744 · Phase 3 · monotherapy
Discontinued due to AEs
—15 mg/kg
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 8 more results
—15 mg/kg
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg/kg IV
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg/kg IV Q4W
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—
NCT03409744 · Phase 3 · monotherapy
Serious AEs
4.5%15 mg/kg
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 8 more results
15.9%15 mg/kg
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg/kg IV
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
7.1%15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
7.1%15 mg
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—15 mg/kg IV Q4W
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
23.3%
NCT03409744 · Phase 3 · monotherapy
Most frequent reported AEs
15 mg/kg
nasopharyngitis 15.9% (placebo 23.8%)
influenza like illness 11.4% (placebo 0%)
headache 9.1% (placebo 23.8%)
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 6 more results
15 mg/kg
headache 11.4% (placebo 23.8%)
nasopharyngitis 11.4% (placebo 23.8%)
back pain 6.8% (placebo 0%)
NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
15 mg
cough 33.3%
oropharyngeal pain 33.3%
rhinitis allergic 33.3%
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
15 mg
covid-19 66.7%
cough 33.3%
pyrexia 33.3%
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
15 mg
oropharyngeal pain 21.4%
abdominal pain upper 14.3%
diarrhoea 14.3%
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
15 mg
covid-19 71.4%
headache 28.6%
oropharyngeal pain 28.6%
NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
nasopharyngitis 19.8%
covid-19 16.4%
headache 16.4%
NCT03409744 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evinacumab's landscape · SHR-1918's landscape